Document:

EX-10.1

 Exhibit 10.1 

12 December 2020 
 Mark Watson, Dana Ono and Debra Peattie

 Inhibitor Therapeutics, Inc. Special Committee 

wmwatson@wmwatson.com 
 Dear INTI Special Committee 

Loan offer 
 Mayne Pharma Ventures Pty Ltd (Mayne Pharma)
offers a loan to Inhibitor Therapeutics, Inc. (INTI) from 14 December 2020 in USD up to the Facility Limit for Purpose (both as defined below) as set out in this letter. This offer takes into account our negotiations with the INTI
Special Committee over the last few weeks. It remains open for acceptance by INTI by signing a copy and returning it by email to generalcounsel@maynepharma.com before 5pm Monday 14 December 2020 US Eastern Standard Time, unless withdrawn
or amended earlier by written notice to INTI by Mayne Pharma. 
 INTI has told Mayne Pharma that it has been encountering serious obstacles raising funds
due to its having been named as a nominal defendant in derivative litigation in Delaware Chancery Court initiated by Hedgepath LLC in 2019 (HPLLC Litigation). The HPLLC Litigation also names Mayne Pharma and certain current and former
directors and officers of INTI. It is anticipated that, absent a settlement, the HPLLC Litigation is likely to continue for well over a year. As a result of these obstacles, we understand INTI is facing the realistic possibility that it will run out
of funds in the near future. 
 INTI wishes to be funded independently of Mayne Pharma, but as a result of the issues discussed above, the INTI Board has
asked Mayne Pharma to consider providing ongoing funding on an interim basis in the form of a loan while the parties explore the possibility of an early resolution to the HPLLC Litigation. INTI has confirmed that the purpose of the funding is to
obtain working capital to fund ongoing corporate expenses, including costs necessary to comply with legal and regulatory obligations going forward. INTI has stated that any funds received from Mayne Pharma will not be used to pay debts that are
currently outstanding except as otherwise indicated herein. 
 Mayne Pharma urges INTI to obtain professional legal and financial advice regarding this
offer. If INTI accepts this offer, Mayne Pharma may choose to discontinue the funding in its sole and absolute discretion at the end of any annual quarter, by giving INTI at least 30 days’ notice of such discontinuance before the end of that
quarter.     
 Lender: Mayne Pharma Ventures Pty Ltd or its nominated affiliate (Lender/Mayne Pharma) 

Borrower: Inhibitor Therapeutics, Inc. (Company/INTI/Borrower) 

Structure: Term Debt Facility (Facility) 
 Line
Amount: USD231,000 (Facility Limit) 
 Availability: USD81,000 in the first annual quarter of the term starting 14 December 2020 and
USD75,000 in each of the subsequent second and third annual quarters, unless Mayne Pharma, acting in its sole and absolute discretion, gives notice to INTI at least 30 days before the start of a quarter that it is discontinuing funding and that INTI
will not be able to draw down additional funds. 

  
 1 

 Purpose: General working capital and corporate purposes as the Board of INTI considers appropriate to
meet its legal and regulatory requirements, payment of the outstanding accounts payable and the transaction costs listed on Schedule 1 hereto, and payment of other outstanding accounts payable as approved in writing by Lender acting in its sole and
absolute discretion (and in any event, excluding already outstanding general and corporate legal fees). 
 Initial Minimum Draw: USD25,000 on written
request by INTI. 
 Maturity: 24 months from first drawdown. 

Payment Terms: One twelve (12) month repayment free advance period from the first drawdown. Each advance against the Facility will be amortized
over twelve (12) equal monthly payments of principal plus interest respectively. Payments on the Facility shall be made in arrears in USD on the due date and in freely transferable same day funds. 

Interest Rate: The payment on this Facility shall be calculated using an interest rate tied to the US Bank Prime Rate (Benchmark Rate). The
Interest Rate quoted in this Proposal shall be equal to the sum of 500 basis points plus the Benchmark Rate. The Interest Rate shall be adjusted for each draw in accordance with changes in the monthly average of the US Bank Prime Rate, as reported
in the Federal Reserve Statistical Release H .15 for the month preceding the week in which the Company shall make a draw against the Facility. 
 Rate
Adjustment: Not applicable. 
 Prepayment / Early Termination: No premium is payable in the event that Borrower pays all principal, interest and
other outstanding amounts due to Lender prior to the maturity date. 
 Terminal Payment: Not applicable 

Financial Covenants: None 
 Warrants: None 

Personal Guarantees: None 
 Negative Covenants:
Without prior written consent, Borrower will not: 
 1) Pledge or otherwise encumber assets (including its intellectual property) except for liens on
specific equipment to secure financing incurred to purchase such equipment. 
 2) Enter into additional borrowings or guarantees, except for trade debt and
capital lease obligations (not to exceed USD50,000) incurred in the ordinary course of business. 
 3) Repurchase capital stock, except as required under
employment agreements or as disclosed per public filing plan. 
 4) Enter into mergers or acquisitions. 

5) Pay cash dividends, make loans to shareholders or other parties, or make investments in other entities. 

Without limiting the foregoing, Borrower may consider a range of transactions to remain a going concern without obtaining prior written consent from Mayne
Pharma. 
 Takedown Period: The Facility will be available for drawdown for a period of nine (9) months from 10 December 2020, or until the
facility is fully drawn subject to Borrower’s compliance with financial covenants and availability, as applicable. No draw will be less than USD25,000. 

Collateral: None. 

  
 2 

 Representations and warranties 

The Borrower represents and warrants to the Lender that: 
  

	 	•	 	 (status) it is properly registered and incorporated as a corporation and validly exists in its jurisdiction of
incorporation; and 

  

	 	•	 	 (power and authority) it has the power, right and necessary corporate authority to enter into this note, and to
exercise its rights and observe and perform its obligations under this note, 

 which representations and warranties are repeated by the
Borrower with reference to the facts and circumstances at the time, on the date of this document, on each date that an advance is made and each date on which any of the money owing is paid to the Lender. 

Financial Statements: If Mayne Pharma so requests, Borrower will provide quarterly financial reports to Mayne Pharma detailing Borrower’s use of
funds Borrower receives under this Facility. 
 Additional Funding: In the event the need arises for INTI to make expenditures that it does not
currently anticipate, INTI may request additional funding from Mayne Pharma, including but not limited to bridge financing pending receipt of funds from a potential capital raise or pending receipt of funds pursuant to a pending or potential
settlement of litigation, for Mayne Pharma’s consideration acting in its sole and absolute discretion. 
 Default 

If: 
  

	 	•	 	 the Borrower breaches its obligations under this note, and where that breach is capable of remedy it does not
remedy the breach within 20 business days after receipt of a notice from the Lender of the breach, 

  

	 	•	 	 Mayne Pharma validly terminates the Third Amended and Restated Supply and License Agreement dated
December 17, 2018 between the parties, or 

  

	 	•	 	 the Borrower becomes insolvent, including by becoming the subject of the filing or institution of bankruptcy,
liquidation or dissolution proceedings, 

 then the Lender may by notice in writing to the Borrower declare that any amounts owing are
immediately due and payable, in which case the Borrower must immediately pay to the Lender those amounts. 
 Dispute Resolution, Choice of Law, and
Limitation of Liability: If any of the parties shall be required to bring any legal action against one another to enforce any of the terms of this Agreement, the prevailing party shall be entitled to recover attorney’s fees and costs; and
during this period, both parties shall not communicate about the dispute with any third parties. Any dispute related to or arising out of this Agreement shall be resolved by arbitration in New York City before the American Arbitration Association
under its Commercial Arbitration Rules. The Agreement shall be governed by the laws of the State of Delaware, USA without regard to the conflicts of law principles thereof. Lender shall not be liable for indirect or consequential damages, and in no
event shall be liable for payment of any sum in excess of the unfunded portion of the Facility Limit. 
 As mentioned above, this offer remains open for
acceptance by INTI by signing a copy and returning it by email to generalcounsel@maynepharma.com before 5pm Monday 14 December 2020 US Eastern Standard Time, unless withdrawn or amended earlier by written notice to INTI by Mayne Pharma.

 Yours sincerely, 
 /s/ Kate Rintoul 

Kate Rintoul 
 Executive Vice President and General Counsel 

kate.rintoul@maynepharma.com 

  
 3 

 
	
	Accepted and agreed to by Inhibitor Therapeutics, Inc. by an authorised officer
	
	 /s/ Nicholas J. Virca

	Signature
	
	Nicholas J. Virca
	  

	Name
	
	December 12, 2020
	  

	Date

  
 4Exhibit 4.1

 

AMENDMENT
No. 1

to

SECTION
382 RIGHTS AGREEMENT

by
and between

RUBICON
TECHNOLOGY, INC.

and

AMERICAN
STOCK TRANSFER & TRUST COMPANY, LLC

 

This
Amendment No. 1 to the Section 382 Rights Agreement (this “Amendment”) is made and entered into as of
December 18, 2020 by and between Rubicon Technology, Inc., a Delaware corporation (the “Corporation”), and
American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”).

 

WHEREAS,
the Corporation and the Rights Agent are parties to that certain Section 382 Rights Agreement, dated as of December 18, 2017 (the
“Rights Agreement”);

 

WHEREAS,
the Rights Agreement, under its current terms, will expire on December 18, 2020;

 

WHEREAS,
the Corporation may amend the Rights Agreement pursuant to Section 26 thereof;

 

WHEREAS,
the Board of Directors of the Corporation has determined that it is in the best interests of the Corporation and its stockholders
to extend the Final Expiration Date until December 18, 2023 in accordance with the terms set forth in this Amendment; and

 

WHEREAS,
at the Company’s 2020 Annual Meeting of Stockholders, the stockholders of the Company ratified the Rights Agreement and
approved a three year extension thereof.

 

NOW
THEREFORE, in consideration of the premises and mutual agreements herein set forth, the parties hereby agree as follows:

 

1. Amendments.

 

(a) Section
1(y) of the Rights Agreement is hereby amended and restated to read as follows: ““Final Expiration Date” shall
be December 18, 2023.”

 

(b) All
references to “December 18, 2020” in Exhibit B (Form of Rights Certificate) and Exhibit C (Summary
of Rights) to the Rights Agreement are amended to replace each such reference with “December 18, 2023.”

 

     

     

    

 

2. Capitalized
Terms. Capitalized terms not defined herein shall have the meanings given such terms in the Rights Agreement.

 

3. Descriptive
Headings. Descriptive headings of the several Sections of this Amendment are included for convenience of reference only and
shall not control or affect the meaning or construction of any of the provisions hereof.

 

4. Governing
Law. This Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall
be governed by and construed and enforced in accordance with the laws of such state applicable to contracts to be made and performed
entirely within such State.

 

5. Counterparts.
This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and the same instrument.

 

6. Effect
of Amendment. Except as expressly modified by this Amendment, the Rights Agreement remains in full force and effect and is
hereby ratified and confirmed.

 

[Remainder
of page left intentionally blank]

 

    2

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed, all as of the day and year first above written.

 

	RUBICON TECHNOLOGY, INC.	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC,	 
	as Rights Agent	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

 

 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]